- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Hospital Formulations for Palliative Medicine
-
- Nagaoka Hiroka
- Center for Palliative and Supportive Care, University of Tsukuba Hospital
Bibliographic Information
- Other Title
-
- 緩和医療が求める院内製剤~医師の視点から~
- Symposium Review 緩和医療が求める院内製剤 : 医師の視点から
- Symposium Review カンワ イリョウ ガ モトメル インナイ セイザイ : イシ ノ シテン カラ
Search this article
Description
Palliative care had a role in maintaining and improving the patient's QOL. To optimize symptomatic management, that cannot be controlled using commercial formulations, in-house pharmaceutical preparations customized to meet an individual's clinical needs are sometimes administered. Despite a growing arsenal of oncology drugs, opioids, and other compounds, many elderly cancer patients have a wide spectrum of comorbid conditions that require the help of skilled pharmacists. Although drugs prepared in in-house pharmacies can be customized to the conditions of individual patients, their preparation is time- and resource-intensive, and their benefits sometimes do not outweigh the costs. In addition, it is often difficult to predict the required amount of a drug that will be dispensed to a very small number of patients via these custom formulations. However, we occasionally experience cases in which hospital formulations (HF) significantly alleviate symptoms and improve the QOL of patients with cancer. In fact, efforts to develop HF of palliative medications sometimes pave the way to new marketable products. In fact, collaborations between physicians and pharmacists have indeed produced new types of medications, which have been further developed into commercial painkillers by drug manufacturers. This article presents examples of HF used in clinical practice. It also discusses the future need for HF, taking note of the ongoing shift towards outpatient oncology care. Regarding the use of HF, we believe it is always important to ensure patient safety, to obtain informed consent, and to follow up.<br>
Journal
-
- YAKUGAKU ZASSHI
-
YAKUGAKU ZASSHI 138 (6), 757-762, 2018-06-01
The Pharmaceutical Society of Japan
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001288062510080
-
- NII Article ID
- 130007382195
-
- NII Book ID
- AN00284903
-
- ISSN
- 13475231
- 00316903
-
- NDL BIB ID
- 029096302
-
- PubMed
- 29863042
-
- Text Lang
- ja
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed